Seres Therapeutics, Inc. (NASDAQ:MCRB) has been given an average recommendation of "Buy" by the eight analysts that are currently covering the firm, Marketbeat Ratings reports. One analyst has rated the stock with a sell recommendation, one has issued a hold recommendation and six have issued a buy recommendation on the company. The average 12 month price target among analysts that have issued a report on the stock in the last year is $37.40.
MCRB has been the topic of several recent research reports. Zacks Investment Research lowered Seres Therapeutics from a "hold" rating to a "sell" rating in a report on Thursday, February 25th. JMP Securities initiated coverage on Seres Therapeutics in a report on Wednesday, December 23rd. They set a "market perform" rating on the stock. Chardan Capital raised Seres Therapeutics from a "neutral" rating to a "buy" rating and lifted their price objective for the stock from $27.50 to $30.00 in a report on Thursday, March 11th. Finally, Oppenheimer reissued a "buy" rating and set a $38.00 price objective on shares of Seres Therapeutics in a report on Tuesday, March 2nd.
Several institutional investors have recently bought and sold shares of the stock. BlackRock Inc. lifted its position in shares of Seres Therapeutics by 4.2% during the 4th quarter. BlackRock Inc. now owns 6,273,836 shares of the biotechnology company's stock worth $153,710,000 after buying an additional 252,551 shares during the period. Sumitomo Mitsui Trust Holdings Inc. lifted its position in shares of Seres Therapeutics by 5.3% during the 4th quarter. Sumitomo Mitsui Trust Holdings Inc. now owns 5,823,603 shares of the biotechnology company's stock worth $142,678,000 after buying an additional 291,933 shares during the period. Nikko Asset Management Americas Inc. lifted its position in shares of Seres Therapeutics by 5.3% during the 4th quarter. Nikko Asset Management Americas Inc. now owns 5,823,603 shares of the biotechnology company's stock worth $142,678,000 after buying an additional 291,933 shares during the period. Federated Hermes Inc. lifted its position in shares of Seres Therapeutics by 5.9% during the 4th quarter. Federated Hermes Inc. now owns 2,953,070 shares of the biotechnology company's stock worth $72,350,000 after buying an additional 163,403 shares during the period. Finally, Janus Henderson Group PLC lifted its position in shares of Seres Therapeutics by 38.2% during the 4th quarter. Janus Henderson Group PLC now owns 2,645,274 shares of the biotechnology company's stock worth $64,810,000 after buying an additional 731,197 shares during the period. Institutional investors and hedge funds own 94.32% of the company's stock.
Shares of MCRB stock traded up $0.03 during trading on Friday, reaching $20.59. The company had a trading volume of 63,246 shares, compared to its average volume of 1,070,948. The company has a market capitalization of $1.88 billion, a PE ratio of -17.64 and a beta of 4.07. The firm's 50 day simple moving average is $20.52 and its two-hundred day simple moving average is $26.05. The company has a debt-to-equity ratio of 0.13, a current ratio of 6.73 and a quick ratio of 6.73. Seres Therapeutics has a one year low of $3.35 and a one year high of $38.50.
Seres Therapeutics (NASDAQ:MCRB) last released its earnings results on Monday, March 1st. The biotechnology company reported ($0.23) earnings per share (EPS) for the quarter, beating the Zacks' consensus estimate of ($0.28) by $0.05. Seres Therapeutics had a negative return on equity of 2,867.98% and a negative net margin of 385.22%. Analysts forecast that Seres Therapeutics will post -1.14 earnings per share for the current year.
About Seres Therapeutics
Seres Therapeutics, Inc, a microbiome therapeutics platform company, engages in developing bacterial consortia that are designed to functionally interact with host cells and tissues to treat disease. The company's lead product candidate is the SER-109, an oral microbiome therapeutic candidate that has completed Phase III clinical trial for the treatment of clostridium difficile infection (CDI).
Read More: Percentage Gainers
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to [email protected]
Featured Article: What are the risks of holding treasury bonds?7 Stocks It May Be Time To Take Profits On
Should you or shouldn’t you? Many investors are wondering if it’s time to take some profit. With so much uncertainty in the market, there can be a temptation to take your profits and run. That may or may not be a good strategy. It’s true there are some speculative stocks that are going up on nothing but faith, trust, and pixie dust. But there are other stocks that may still be good buys despite continuing to grow.
Since the sell-off caused by the novel coronavirus and subsequent locking down of large portions of the economy, the stock market has recovered nearly all of its losses. The Federal Reserve has done its part by pledging to keep interest rates low for as long as it takes. New housing starts are up. Unemployment is coming down. There seems to be a lot of fuel for market bulls.
Still, if you’ve been holding one of the stocks in this presentation, it may be time for you to take some of the profits you’ve made. Many of the stocks in this presentation are being downgraded by analysts. And that means that there is likely to be downward pressure on the stock price.
View the "7 Stocks It May Be Time To Take Profits On"